Dr. med. Sarah Fischer

Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Liver Fat Quantification: Agreement and Reproducibility of Ultrasound-Derived Fat Fraction Measurements Using 5C1 and DAX Probes in Subjects Stratified by BMI Übereinstimmung und Reproduzierbarkeit ultraschallbasierter Fettfraktionsmessungen mit 5C1- und DAX-Sonden bei Probanden unterschiedlicher BMI-Kategorien (2026) Lamprecht-Bailer R, Fischer S, Haberkamp S, Schmid J, Neurath M, Zundler S, Klett D Journal article Superb Microvascular Imaging Is Superior to Doppler Imaging in Ruling Out Ulcerative Colitis Disease Activity (2025) Haberkamp S, Fischmann D, Wilde J, Strobel D, Vetter M, Wolf L, Vitali F, et al. Journal article IBUS-SAS Is a Highly Accurate Intestinal Ultrasound Score for Predicting Endoscopic Disease Activity in Ulcerative Colitis (2025) Fischer S, Fischmann D, Wilde J, Vetter M, Wolf L, Geppert CI, Atreya R, et al. Journal article Automated inflammatory bowel disease detection using wearable bowel sound event spotting (2025) Baronetto A, Fischer S, Neurath M, Amft O Journal article Accuracy of superb microvascular imaging (SMI) in predicting endoscopic Crohn's disease activity (2025) Haberkamp S, Fischmann D, Wilde J, Fischer S, Vetter M, Wolf L, Vitali F, et al. Journal article Relevance of capsule endoscopy in patients with obscure gastrointestinal bleeding - a comprehensive real-world study. (2025) Vetter M, Gebhardt S, Kessler G, Jesper D, Fischer S, Hagel A, Siebler J, et al. Journal article Update zur Pathophysiologie, Prädiktion und Prävention chronisch-entzündlicher Darmerkrankungen (2025) Fischer S, Neurath M Journal article Risk factors associated with complications of palliative drainage of ascites with tunneled peritoneal catheters (2025) Machnik D, Fischer S, Vetter M, Lamprecht-Bailer R, Rouse-Merkel R, Klett D, Neurath M, et al. Journal article Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial. (2025) Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath M, et al. Journal article Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study (2024) Fischer S, Donhauser M, Cohnen SE, Fietkau K, Vetter M, Grübel-Liehr M, Dietrich P, et al. Journal article